Capnopharm develops aerosol-based chemotherapies and immunotherapies for peritoneal and pleural cancer patients. 

Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), a minimally invasive aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology – from re-formulation of existing chemotherapy drugs to next-generation drugs involving Nanoparticles, DNA, mRNA or Immunotherapeutics.

Together with our pharmaceutical clients, we explore drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.

Capnopharm GmbH

Org chart

Teams

Offices